Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19

被引：76
|
作者：
Praveen, D. [1 ]
Puvvada, Ranadheer Chowdary [1 ]
Aanandhi, Vijey M. [2 ]
机构：
[1] Vels Inst Sci Technol & Adv Studies, Sch Pharmaceut Sci, Chennai 600117, Tamil Nadu, India
[2] Vels Inst Sci Technol & Adv Studies, Sch Pharmaceut Sci, Dept Pharmaceut Chem & Anal, Chennai, Tamil Nadu, India
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2020年 / 55卷 / 05期
关键词：
SARS-CoV-2; COVID; 19; Baricitinib; Novel Corona Virus;
D O I：
10.1016/j.ijantimicag.2020.105967
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19
    Finsterer, Josef
    Scorza, Fulvio A.
    BRAIN HEMORRHAGES, 2021, 2 (04): : 151 - 152
  • [2] The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
    Gozzetti, Alessandro
    Capochiani, Enrico
    Bocchia, Monica
    LEUKEMIA, 2020, 34 (10) : 2815 - 2816
  • [3] The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
    Alessandro Gozzetti
    Enrico Capochiani
    Monica Bocchia
    Leukemia, 2020, 34 : 2815 - 2816
  • [4] Role of baricitinib and sotrovimab in the management of COVID-19
    Darmadi, Darmadi
    Pakpahan, Cennikon
    Surja, Sem Samuel
    RAWAL MEDICAL JOURNAL, 2024, 49 (03): : 678 - 681
  • [5] Janus-Kinase-Inhibitor Baricitinib in rheumatoid Arthritis
    Alten, R.
    Nitschmann, S.
    INTERNIST, 2017, 58 (12): : 1341 - 1344
  • [6] Janus kinase inhibitors for the treatment of COVID-19
    Kramer, Andre
    Prinz, Carolin
    Fichtner, Falk
    Fischer, Anna-Lena
    Thieme, Volker
    Grundeis, Felicitas
    Spagl, Manuel
    Seeber, Christian
    Piechotta, Vanessa
    Metzendorf, Maria-Inti
    Golinski, Martin
    Moerer, Onnen
    Stephani, Caspar
    Mikolajewska, Agata
    Kluge, Stefan
    Stegemann, Miriam
    Laudi, Sven
    Skoetz, Nicole
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (06):
  • [7] The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
    La Rosee, F.
    Bremer, H. C.
    Gehrke, I
    Kehr, A.
    Hochhaus, A.
    Birndt, S.
    Fellhauer, M.
    Henkes, M.
    Kumle, B.
    Russo, S. G.
    La Rosee, P.
    LEUKEMIA, 2020, 34 (07) : 1805 - 1815
  • [8] The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
    F. La Rosée
    H. C. Bremer
    I. Gehrke
    A. Kehr
    A. Hochhaus
    S. Birndt
    M. Fellhauer
    M. Henkes
    B. Kumle
    S. G. Russo
    P. La Rosée
    Leukemia, 2020, 34 : 1805 - 1815
  • [9] Direct Effects of the Janus Kinase Inhibitor Baricitinib on Sensory Neurons
    Vazquez, Enrique
    Richter, Frank
    Natura, Gabriel
    Koenig, Christian
    Eitner, Annett
    Schaible, Hans-Georg
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (22)
  • [10] Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib
    Sarny, Stephanie
    Hucke, Miriam
    El-Shabrawi, Yosuf
    JAMA OPHTHALMOLOGY, 2018, 136 (12) : 1420 - 1422
12345